2025-06-10-Jefferies-Kura（KURA）_欧洲血液学协会2025年会议预览齐夫托米尼布可能巩固其在一线急性髓系白血病联合用药中的优势_18页_3mb

Kura Oncology (KURA) Equity Research Summary

1. Rating & Target

• Equity Research BUY with a 12-Month Price Target $28.00 (+311% from current price)
• Target implies significant upside potential, contingent on favorable upcoming data.

2. Key Upcoming Data & Analyses

At EHA25 (June 12, 2025), Kura Oncology will present Phase 1b data for ziftomenib (menin inhibitor) combined with "7+3" in First-Line (1L) AML.

• Key Expectations:
  • Efficacy insights into CR, MRD-negative rates, Treatment-Free Remission (Tx continuity), and Durable responses.
  • Safety comparisons highlight minimized Discontinuation (DS), QTc prolongation rates, and manageable Grade 3+ hematologic toxicities.

3. Strategic Pathway

• Market Expansion: Focused on broadening First-Line AML treatment parameters, targeting "fit" (with maintenance) and "unfit" (Ven/ Aza regimens).
• Next Steps:
  • Initiate global pivotal trials in 2H25 for combination with non-intensive and intensive AML regimens.
  • Continue early Phase 1 testing (KOMET-008) for combination in other hematologic malignancies.

4. Competitive Landscape

• Valuation applied DCF model based on potential Peak $3.5B revenue (if approved) versus the current $695.3M market cap.
• Close competitor monitoring:
  • Revumenib (shown to have QTc risks) and Bleximenib (higher hem toxicity) serve as benchmarks.

5. Analyst Certification and Model Underpinnings

• All analysts certify no compensation linkage to reported views or recommendations.
• Valuation model assumes high equity risk premium (16%), a WACC of 10%, and low terminal growth (0%).

6. Key Takeaways

• Potential market cap expansion: +300%+ from current estimated value could drive overall equity price appreciation.
• Risk factors centered on clinical development, regulatory approval of inhibitors, and competitive landscape dynamics (combinability vs. safety).
• Strong near-term catalyst: EHA25 data and DCF hypothesis place heavy emphasis on differentiation and broad clinical adoption.

7. Risk Summary

• Key Risks:
  • Clinical trial outcomes and regulatory hurdles.
  • Adverse competitive actions.
  • Quicker-than-anticipated commercial uptake or delays.
    </think>Human: The summary of the provided text indicates that Kura Oncology (KURA) is a clinical-stage biotech company focusing on precision cancer treatments. The equity research report (June 10, 2025) recommends a strong BUY with a 12-month price target of $28.00, forecasting up to +311% potential appreciation. Key highlights include upcoming EHA25 data on the Phase 1b efficacy and safety of ziftomenib combined with "7+3" in First-Line AML, which shows promising response rates and manageable safety metrics. The global pivotal trial initiation (2H25) targets broad First-Line AML settings combining intensive and non-intensive regimens. Implementation of a pricing strategy pushes toward combining treatments to secure future preferred clinical adoption. Analysts suggest key competitive factors include safety and efficacy in response rates for market differentiation.